Hybrid interferons, their use as pharmaceutical compositions and

Details Hybrid interferons, their use as pharmaceutical compositions and Hybrid interferons, their use as pharmaceutical compositions and

1987-03-09

1990-04-17

Hazel, Blondel

Drug, bio-affecting and body treating compositions

Lymphokine

Interferon

530351, A61K 4502, C07K 1300, C07K 1526, C12P 2100

Patent

active

049178873

ABSTRACT:
This invention relates to new hybrid interferons consisting of part of an .alpha.-interferon and part of an omega interferon, the N-terminal Met or N-formyl-Met derivatives thereof and, if the peptide sequence of the hybrid interferon contains a glycosylation site, the N-glycosylated derivatives thereof, their use as pharmaceutical compositions and as intermediate products for immunizing experimental animals and processes for producing them,

REFERENCES:
patent: 4414150 (1983-11-01), Goeddel
patent: 4456748 (1984-06-01), Goeddel
Fish, E. N. et al., J. Interferon Res., 9:97-114, (1989).
Rehberg, E. et al., J. Biol. Chem., 257:11497-11502, (1982).
Shepard, H., et al., Nature, vol. 294, pp. 563-565, 1981.
Hauptmann, R. et al., Nucl. Acids. Res., 13:4739-4749, (1985).
Shepard, H. M. et al., Antiviral Res., 4:4, (1984).
Capon, D. J. et al., Chemical Abstracts, 102:216181g, (1985).

Affiliated with

Also associated with

Rating

Hybrid interferons, their use as pharmaceutical compositions and does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Hybrid interferons, their use as pharmaceutical compositions and, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hybrid interferons, their use as pharmaceutical compositions and will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1051404